The U.S. Food and Drug Administration has warned that
patients using a combination of simvastatin and anti-arrhythmia medicine
amiodarone could suffer a rare fatal muscle injury.
The injury called rhabdomyolysis may lead to kidney failure or even death.
The FDA said it had already warned about this condition in 2002, but that patients were still being prescribed this combination.